This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Dermal exposure to MNPs occurs through contact with contaminated media like soil, water, and personal care products, including facial and body scrubs containing MNPs as exfoliants. Although the skin generally acts as a barrier, conditions such as skin lesions or high exposure environments may allow for enhanced absorption of MNPs, particularly nanoplastics, which can penetrate the stratum corneum. Furthermore, workers handling production of textiles, garments, fabric, and other fiber products are constantly exposed through inhalation and direct dermal contact. This highlights the need for further research into the effects MNPs have on human health, especially on industrial workers who have higher rates of exposure. Studies on dermal exposure highlight the potential for these particles to enter systemic circulation, especially if the skin barrier is disrupted by wounds or conditions that increase permeability, like pores such as sweat glands and hair follicles.
==== Nanoenzymes (or nanozymes) ==== The small size of nanoenzymes (or nanozymes) (1–100 nm) has provided them with unique optical, magnetic, electronic, and catalytic properties. Moreover, the control of surface functionality of nanoparticles and the predictable nanostructure of these small-sized enzymes have allowed them to create a complex structure on their surface that can meet the needs of specific applications
== Petrochemistry == In petrochemistry, gelling agents, also called solidifiers, are chemicals capable of reacting with oil spills and forming rubber-like solids. The gelled coagulated oil then can be removed from the water surface by skimming, suction devices, or nets. Calm or only moderately rough sea is required.
For adults between 25 and 64, the effect appears neutral on suicidal behavior, but possibly protective for suicidal behavior for adults between the ages of 25 and 64. For adults older than 64, SSRIs seem to reduce the risk of suicidal behavior. In 2016, a review criticized the effects of the FDA Black Box suicide warning inclusion in the prescription. The authors discussed that the suicide rates might also increase as a consequence of the warning. A 2019 review makes a similar claim, noting that instead of increasing the use of psychotherapy (as the FDA had hoped), the warning has increased the use of benzodiazepines. A 2021 study on Swedish youth and adults between 2006 and 2013 (n = 538,577) finds that the highest frequency of suicides occurs at 30 days before, rather than after, the beginning of SSRI prescription. This pattern indicates that SSRIs do not increase the risk of suicide and may reduce the risk.
rivalries between Nazi leaders for Hitler's favor that led to the "cumulative radicalization" of racial policy was Hitler always favored those with the most radical ideas. the tendency of the Nazis to define the volksgemeinschaft in a negative sense in terms of who was to be excluded together with a xenophobic and paranoid tendency to see Germany as besieged by external and internal enemies. Peukert wrote all "monocausal explanations of the 'Final Solution' are inadequate", but then asked if out of this "tangle of causes" one might find a "central thread" linking them all. Peukert suggested that this "thread" was not antisemitism-through he admitted that Jews were the largest single group of victims of the Nazi regime-but rather the "fatal racist dynamism present within the human and social sciences", which divided all people into terms of "value" and "non-value", and made the volkskörper (the collective "body" of the "German race") its main concern with the "selection" of those with healthy genes and the "eradication" of those with unhealthy genes. In this regard, Peukert noted the genocide against the Jews grew out of the Action T4 program which starting in January 1939 sought to liquidate all physically and mentally disabled Germans as a threat to the health of the volkskörper. Peukert wrote that it was not antisemitism per se that led to genocide, but rather the project to purge the volksgemeinschaft of those seen as carrying unhealthy genes that was the beginning of genocide, which started with the Action T4 program.
Sources: en.wikipedia.org
The bold, powerful cry commonly associated with the bald eagle in popular culture is actually that of a red-tailed hawk. Bald eagle vocalizations are much softer and chirpier, and bear far more resemblance to the calls of gulls. Despite the saying "dumb as a dodo", the dodo's intelligence was above average for an avian, as it was a member of the family Columbidae. The perceived stupidity of the dodo is due to naivety and passivity from living in isolation without significant predators. Many believe that the dodo was hunted to extinction by European settlers due to its high culinary value. However, the dodo's meat was stated to be inedible by historical accounts, as one of its early names given by the Dutch was Walghvoghel (repulsive bird). The dodo's decline was caused more by predation of their eggs from invasive species as opposed to direct predation from humans. A duck's quack actually does echo, although the echo may be difficult to hear for humans under some circumstances. Despite this, a British panel show compiling interesting facts was named Duck Quacks Don't Echo. Ostriches do not stick their heads in the sand to hide from enemies or to sleep. This misconception's origins are uncertain but it was probably popularized by Pliny the Elder (23–79 CE), who wrote that ostriches "imagine, when they have thrust their head and neck into a bush, that the whole of their body is concealed".
Svarthöna, Bohuslän-Dals svarthöna, or Swedish Black Chicken is a Swedish landrace of domestic chickens that is considered to have originated from Ayam Cemani/Kadaknath breeds of chickens transported from Mozambique to Norway by sailors sometime in the 17th century. The Svarthöna has since adapted to a northerly climate, it but has retained the rare quality of black skin and connective tissue. The current form of Svarthöna has been given the status of a landrace. All Swedish entries in gene banks can be traced to a group of chickens that came to Sweden around the turn of the 19th century. In 1956, this flock was bought by two brothers in Bullarebygd. The Swedish Association for Landrace Breeds has preserved the Svarthöna in a gene bank since 1991. A rooster can weigh up to 2 kg, whilst hens do not exceed 1.5 kg. The eggs are small (38-48 g) with a large yolk. The Svarthöna has some flight ability. The black pigmentation found in skin and connective tissue has been shown to be caused by a variant of the gene EDN3, a trait shared with the Chinese Silkie, Indonesian Ayam Cemani, and Vietnamese Black H'Mong.
Synephrine behaved as a partial agonist at α1A receptors, but as an antagonist at α2A and α2C sub-types. Racemic synephrine has been shown to be an agonist of the TAAR1, although its potency at the human TAAR1 is relatively low (EC50 = 23700 nM; Emax = 81.2%).
=== Mineral acids (inorganic acids) === Hydrogen halides and their solutions: hydrofluoric acid (HF), hydrochloric acid (HCl), hydrobromic acid (HBr), hydroiodic acid (HI) Halogen oxoacids: hypochlorous acid (HClO), chlorous acid (HClO2), chloric acid (HClO3), perchloric acid (HClO4), and corresponding analogs for bromine and iodine Hypofluorous acid (HFO), the only known oxoacid for fluorine. Sulfuric acid (H2SO4) Fluorosulfuric acid (HSO3F) Nitric acid (HNO3) Phosphoric acid (H3PO4) Fluoroantimonic acid (HSbF6) Fluoroboric acid (HBF4) Hexafluorophosphoric acid (HPF6) Chromic acid (H2CrO4) Boric acid (H3BO3)
The role of Iraq's Scud missiles featured prominently in the war. Scud is a tactical ballistic missile that the Soviet Union developed and deployed among the forward deployed Soviet Army divisions in East Germany. Scud missiles utilize inertial guidance which operates for the duration that the engines operate. Iraq used Scud missiles, launching them into both Saudi Arabia and Israel. Some missiles caused extensive casualties, while others caused little damage. The US Patriot missile was used in combat for the first time. The US military claimed a high effectiveness against Scuds at the time, but later analysis gives figures as low as 9%, with 45% of the 158 Patriot launches being against debris or false targets. The Dutch Ministry of Defense, which also sent Patriot missiles to protect civilians in Israel and Turkey, later disputed the higher claim. There is at least one incident of a software error causing a Patriot missile's failure to engage an incoming Scud, resulting in deaths. Both the US Army and the missile manufacturers maintained the Patriot delivered a "miracle performance" in the Gulf War.
Sources: en.wikipedia.org
== Awards == Gold Medal of the Society for Magnetic Resonance in Medicine (1989) GE Coolidge Fellow and Medal, (1990) GE Gold (1989), Silver (1985) and Bronze (1982) patent medallions Editors recognition awards from Radiology (1986, 1988, 1989, 1990) GE Dushman Award (1983) Associate editor, Magn Reson Med (1983-2004), deputy editor (2010-2025) Editorial boards of Magn Reson Imag (1982–present), Rev Sci Instrum (1986-1988), and Radiology (1991-5) Editorial board of Advanced Medicine (Japan: 1995–); MAGMA (2003–2006) Elected trustee, Soc Magn Reson Med (1986-1989), and Soc Magn Reson Imag (1982-1986) Fellow, Soc Magn Reson (1989) Gold Medal of the American Roentgen Ray Society (2015) Distinguished investigator, Academy of Radiology Research (2012) Member, National Academy of Inventors (2015) Soc Magn Reson Med Sir Peter Mansfield Lecturer (2012) NIH grant reviewer since 1979
A system of measure for timber in the round (standing or felled), now largely superseded by the metric system except in measuring hardwoods in certain countries. Its purpose is to estimate the value of sawn timber in a log, by measuring the unsawn log and allowing for wastage in the mill. Following the so-called "quarter-girth formula" (the square of one quarter of the circumference in inches multiplied by 1⁄144 of the length in feet), the notional log is four feet in circumference, one inch of which yields the hoppus board foot, 1 foot yields the hoppus foot, and 50 feet yields a hoppus ton. This translates to a hoppus foot being equal to 1.273 cubic feet (2,200 in3; 0.0360 m3). The hoppus board foot, when milled, yields about one board foot. The volume yielded by the quarter-girth formula is 78.54% of cubic measure (i.e. 1 ft3 = 0.7854 h ft; 1 h ft = 1.273 ft3).
This failure to deaminate the AMP molecules has three major effects. First, significant amounts of AMP are lost from the cell and the body. Second, ammonia is not freed when the cell does work. Third, the level of IMP in the cell is not maintained.
== History == Established in 1984, the International Petroleum Investment Company (IPIC) was created to advance Abu Dhabi's natural petroleum wealth for the development of the emirate. Mubadala Development Company followed in 2002 to further diversify the economy. In June 2016, it was announced that Mubadala Development Company would merge with the International Petroleum Investment Company. In 2017, ownership of both MDC and IPIC was transferred to a newly created parent company, Mubadala Investment Company. The company is a wholly owned investment vehicle of the government of Abu Dhabi, and Sheikh Mansour bin Zayed Al Nahyan, vice-president and deputy prime minister of the United Arab Emirates, is chairman of the company.
S. haemolyticus can colonize central venous catheters and cause serious medical complications. Colonization occurs when S. haemolyticus migrates from the skin, along the external surface of the device, or from the hub, due to manipulation by health care workers. In either scenario, a high probability exists that the microbe will form a biofilm. These infections can remain localized or become systemic (i.e. bacteremia). The severity of infection varies depending on the type of catheter, frequency of manipulation, and virulence factors of the S. haemolyticus strain. Removal of the catheter is usually considered to be the best treatment, but this is not always possible. Alternatively, vancomycin or teicoplanin may be administered. Recent evidence suggests that glycopeptides can be supplemented with β-lactams to work synergistically.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.